Perinatology.  2025 Mar;36(1):32-36. 10.14734/PN.2025.36.1.32.

New-Onset Neuromyelitis Optica Spectrum Disorder during Pregnancy: A Case Report

• Lee SH
• Kim S
• Lee SJ
• Kim SH
• Na S

• KMID: 2566683
• DOI: http://doi.org/10.14734/PN.2025.36.1.32

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory disease that most often affects the optic nerves and spinal cord. We describe a case of 36-year-old woman presented at 13 weeks of gestation with 4 extremities paresthesia and weakness that had lasted for two months at her first visit to our hospital. She had two previous uncomplicated full-term vaginal deliveries and no significant medical or family history. Spine magnetic resonance imaging (MRI) showed extensive cervical cord lesion and aquaporin-4 antibodies were strongly positive, confirming the diagnosis of NMOSD. Initial management with high-dose corticosteroids and plasmapheresis was done and she showed substantial improvement, but she revisited hospital at 26 weeks of gestational age due to visual disturbance and aggravated weakness. Relapse of NMOSD was confirmed by spine MRI, so rituximab therapy was initiated at 28 weeks of gestational age for prevention of recurrence. The patient showed clinical improvement with no adverse effects and relapse of symptoms. She successfully delivered a healthy male infant at 39 weeks and 3 days of gestational age through uncomplicated vaginal delivery. This case demonstrates successful management of new-onset NMOSD during pregnancy using a multi-modal treatment approach including rituximab.

Keyword

Neuromyelitis optica; Pregnancy; Rituximab; Plasmapheresis; Immunotherapy